Affymetrix, Oncormed Collaborate to Develop Expression Database | GenomeWeb

SANTA CLARA--Affymetrix and Oncormed announced they will codevelop a gene expression database as a tool to enable the use of gene expression data in drug development by third party subscribers. The new agreement further leverages Oncormed's strength in gene characterization and pharmacogenomics with Affymetrix's GeneChip expression analysis tools. The collaboration is the third in a series of agreements between the companies, representing a relationship that began with the development and validation of a GeneChip assay for identifying mutations in the p53 gene.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.